List of Tables
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Situation by Manufacturers in 2025
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Types and Applications
Table 12. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Companies by Tier (Tier 1, Tier 2, Tier 3), based on Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (K Units), 2021–2026
Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021–2026)
Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (K Units), 2027–2032
Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2027–2032)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (US$ Million), 2021–2026
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021–2026)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (US$ Million), 2027–2032
Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2027–2032)
Table 25. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2021–2026
Table 27. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2027–2032
Table 28. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2021–2026
Table 29. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2021–2026
Table 32. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2027–2032
Table 33. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2021–2026
Table 42. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2027–2032
Table 43. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (US$ Million), 2027–2032
Table 50. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2021–2026)
Table 51. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2027–2032)
Table 52. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2021–2026)
Table 53. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2027–2032)
Table 54. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2021–2026)
Table 57. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2027–2032)
Table 58. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2021–2026)
Table 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2027–2032)
Table 60. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2021–2026)
Table 61. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2027–2032)
Table 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2021–2026)
Table 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2027–2032)
Table 64. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2021–2026)
Table 67. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2027–2032)
Table 68. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2021–2026)
Table 69. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2027–2032)
Table 70. Aptinyx Inc Company Information
Table 71. Aptinyx Inc Description and Business Overview
Table 72. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 74. Aptinyx Inc Recent Developments/Updates
Table 75. Asahi Kasei Pharma Corp Company Information
Table 76. Asahi Kasei Pharma Corp Description and Business Overview
Table 77. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 79. Asahi Kasei Pharma Corp Recent Developments/Updates
Table 80. Regenacy Pharmaceuticals Company Information
Table 81. Regenacy Pharmaceuticals Description and Business Overview
Table 82. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 84. Regenacy Pharmaceuticals Recent Developments/Updates
Table 85. MAKScientific LLC Company Information
Table 86. MAKScientific LLC Description and Business Overview
Table 87. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 89. MAKScientific LLC Recent Developments/Updates
Table 90. Metys Pharmaceuticals AG Company Information
Table 91. Metys Pharmaceuticals AG Description and Business Overview
Table 92. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 94. Metys Pharmaceuticals AG Recent Developments/Updates
Table 95. Nemus Bioscience Inc Company Information
Table 96. Nemus Bioscience Inc Description and Business Overview
Table 97. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 99. Nemus Bioscience Inc Recent Developments/Updates
Table 100. PledPharma Company Information
Table 101. PledPharma Description and Business Overview
Table 102. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 104. PledPharma Recent Developments/Updates
Table 105. Sova Pharmaceuticals Inc Company Information
Table 106. Sova Pharmaceuticals Inc Description and Business Overview
Table 107. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 109. Sova Pharmaceuticals Inc Recent Developments/Updates
Table 110. DermaXon LLC Company Information
Table 111. DermaXon LLC Description and Business Overview
Table 112. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 114. DermaXon LLC Recent Developments/Updates
Table 115. Kineta Inc Company Information
Table 116. Kineta Inc Description and Business Overview
Table 117. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 119. Kineta Inc Recent Developments/Updates
Table 120. Krenitsky Pharmaceuticals Inc Company Information
Table 121. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 122. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 124. Krenitsky Pharmaceuticals Inc Recent Developments/Updates
Table 125. PeriphaGen Company Information
Table 126. PeriphaGen Description and Business Overview
Table 127. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 129. PeriphaGen Recent Developments/Updates
Table 130. Apexian Pharma Company Information
Table 131. Apexian Pharma Description and Business Overview
Table 132. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 134. Apexian Pharma Recent Developments/Updates
Table 135. WinSanTor Company Information
Table 136. WinSanTor Description and Business Overview
Table 137. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 139. WinSanTor Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 143. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 144. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 145. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 146. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 147. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type: 2025 & 2032
Figure 4. Calcium Channel α2-delta Ligands Product Picture
Figure 5. Antidepressants Product Picture
Figure 6. Opioids Product Picture
Figure 7. Others Product Picture
Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application: 2025 & 2032
Figure 10. Platinum Agents
Figure 11. Taxanes
Figure 12. Vinca Alkaloids
Figure 13. Others
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million), 2021–2032
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), 2021–2032
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit), 2021–2032
Figure 18. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 19. Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers in 2025
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Chemotherapy Induced Peripheral Neuropathy Treatment Players: Market Share by Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment in 2025
Figure 22. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021–2032)
Figure 25. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2021–2032)
Figure 26. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021–2032)
Figure 29. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2021–2032)
Figure 30. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2021–2032)
Figure 37. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Malaysia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Philippines Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021–2032)
Figure 48. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2021–2032)
Figure 49. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2021–2032)
Figure 54. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. U.A.E Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2021–2032)
Figure 58. Global Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Type (2021–2032)
Figure 59. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Type (2021–2032)
Figure 60. Global Sales Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2021–2032)
Figure 61. Global Revenue Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment by Application (2021–2032)
Figure 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (US$/Unit) by Application (2021–2032)
Figure 63. Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
